Overview
GLOW is a proprietary peptide blend formulated to target skin health, rejuvenation, and recovery through multi-pathway activation. The typical composition combines three peptides at specific ratios: GHK-Cu as the dominant component (driving collagen gene expression), BPC-157 for tissue repair and cytoprotective signaling, and thymosin beta-4 (TB-4) for cell migration and wound closure.
The rationale for blending is synergistic multi-pathway targeting. Rather than relying on a single mechanism, GLOW addresses collagen synthesis (GHK-Cu), tissue protection and anti-inflammation (BPC-157), and cellular migration/wound healing (TB-4) simultaneously. Common ratios are GHK-Cu 50 mg / BPC-157 10 mg / TB-4 10 mg, with GHK-Cu dominant because it drives the primary collagen gene expression cascade.
The evidence gap: While each individual component has its own research base (ranging from excellent for GHK-Cu to nonexistent in humans for TB-500), no published study has evaluated the GLOW blend as a specific formulation. The assumption of synergy is theoretical — it has not been validated. Proprietary blends also make it impossible to attribute observed effects to any specific component.
Dosage & Reconstitution
- Vial strength
- 70 mg
- BAC water added
- 3 mL
- Final concentration
- ~23.3 mg/mL
| Weeks | Dosage | Syringe units (U-100) |
|---|---|---|
| Weeks 1–4 | 2.33 mg | 10 units0.1 mL |
FrequencyOnce daily, subcutaneous, as a four-week course followed by two to four weeks off.
Note
For review — no human dosing exists for this blend. GLOW has never been studied as a combination: there is no trial, no validated ratio and no established frequency, and the single row in the chart follows a circulated research protocol. The concentration strip above the chart is calculated from the vial and water volume and is correct.
Unverified — no study of the blend establishes a course length or a frequency.
The 70 mg vial strength charted here is the composition Athena documents further down this page — GHK-Cu 50 mg with BPC-157 10 mg and TB-500 10 mg — so a 2.33 mg amount delivers roughly 1.67 mg of GHK-Cu and 0.33 mg of each of the other two, in a ratio fixed by the vial rather than chosen. There is no trial of the combination, no validated ratio and no established frequency, so the single row and the four-week course are a circulated protocol and are flagged for review; the components also have unequal evidence individually, and none of it was generated with them co-administered. Made up with 3 mL the vial is about 23.3 mg/mL, which puts the daily amount at 10 units — comfortably inside a 50-unit syringe, and about a thirtieth of the vial. Because the three peptides are fixed in one vial they cannot be titrated separately the way each was studied on its own.
What this evidence establishes. No human dosing exists for the GLOW blend. It has never been studied as a blend — there is no trial of the combination, no validated ratio and no established frequency. Its components have unequal evidence behind them individually, and none of that evidence was generated with the components co-administered. Because a blend is supplied at a fixed ratio in a single vial, the amount of each component is set by the vial rather than chosen, so component-level figures from separate studies cannot be applied to it.
For educational and laboratory research purposes only. It does not provide medical advice, dosing recommendations, or instructions for human or veterinary use. Syringe units assume a U-100 syringe, on which 1 mL is 100 units and a 50-unit syringe holds 0.5 mL.
Component Profiles
Each component of the GLOW blend has its own evidence base, regulatory status, and risk profile. Click through to the full compound pages for comprehensive profiles:
GHK-Cu (Dominant)
Modulates 4,000+ genes. Stimulates collagen I/III synthesis. 2025 meta-analysis confirms wrinkle reduction. Cosmetic-cleared in US + EU. Full Profile →
BPC-157
Cytoprotective pentadecapeptide. Anti-inflammatory, pro-angiogenic. 544+ preclinical articles. 3 small human studies. FDA Category 2. Full Profile →
TB-4 (Thymosin Beta-4)
Actin-binding peptide promoting cell migration and wound closure. Anti-fibrotic. Zero human clinical trials for TB-500. FDA Category 2. Full Profile →
Proposed Synergistic Mechanism
Phase 1: Gene Expression
GHK-Cu activates collagen, elastin, and ECM remodeling genes. Sets the cellular program for skin regeneration at the transcription level.
Phase 2: Tissue Protection
BPC-157 provides cytoprotective signaling — reducing inflammatory damage and supporting cellular survival during the remodeling process.
Phase 3: Cell Migration
TB-4 promotes endothelial and progenitor cell migration to target sites, facilitating wound closure and tissue regeneration.
Phase 4: Vascularization
Both BPC-157 and TB-4 promote angiogenesis through different pathways, increasing blood supply to support new tissue formation.
Evidence Status
This multi-phase model is THEORETICAL. No published research has validated the synergistic interaction of these three compounds in combination.
Attribution Problem
In a blend, it's impossible to determine which component is producing observed effects. This is why single-compound studies exist — blends obscure cause and effect.
Contraindications & Safety Data
Blend-specific safety data does not exist. Contraindications are derived from the individual component profiles. The most restrictive component determines the blend's overall risk level.
| Condition / Factor | Risk Level | Limiting Component | Rationale |
|---|---|---|---|
| Active cancer or malignancy | HIGH | BPC-157, TB-4 | Both promote angiogenesis. TB-4 levels are elevated in some metastatic cancers. Pro-angiogenic compounds may support tumor vascularization. |
| Cancer history | HIGH | TB-4 | Angiogenesis and cell migration promotion pose theoretical risk for dormant cancer reactivation |
| Pregnancy / breastfeeding | HIGH | All three | No reproductive toxicology data for any component in this combination |
| Proliferative retinopathies | HIGH | TB-4 | Pro-angiogenic activity is specifically contraindicated where pathological blood vessel growth occurs |
| Wilson's disease / copper disorder | HIGH | GHK-Cu | Exogenous copper is contraindicated in Wilson's disease |
| Autoimmune conditions | MODERATE | BPC-157, TB-4 | Immune-modulating properties may unpredictably affect autoimmune disease |
| No blend-specific data | UNKNOWN | All | Zero published studies on the combined formulation. Drug-drug interactions between components are unstudied. |
Regulatory Status
The blend: GLOW as a proprietary formulation has no regulatory clearance. The FDA does not evaluate proprietary blends individually.
GHK-Cu: Permitted in cosmetic formulations (US + EU). Not WADA prohibited. The only component with regulatory clearance.
BPC-157: FDA Category 2 — prohibited for compounding. WADA prohibited (S0).
TB-500/TB-4: FDA Category 2 — prohibited for compounding. WADA prohibited (S0).
Net regulatory position: Because the blend contains two FDA Category 2 substances (BPC-157 and TB-4), the blend as a whole cannot be legally compounded in the United States regardless of GHK-Cu's cosmetic clearance. The regulatory status of the most restricted component applies to the entire formulation.
References
GLOW Blend Knowledge Quiz
Test your understanding of the GLOW blend's evidence base, component profiles, and regulatory reality.